Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78213 | 0.90 | — | — | |
| SCHEMBL18867938 | 0.90 | — | — | |
| Iodide SCHEMBL28852430 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL10901713 | 0.87 | — | — | |
| Fluoride SCHEMBL28011565 | 0.87 | CA1 (0.57) | CA1CA9MEN1NPC1RAB9A | |
| SCHEMBL8856015 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL16337920 | 0.87 | CA1 (0.57) | CA1CA9MEN1NPC1RAB9A | |
| SCHEMBL11578634 | 0.87 | — | — | |
| SCHEMBL12503774 | 0.87 | — | — | |
| SCHEMBL27564121 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729095-B2 | 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20120245152-A1 | 3-(BIARYOXY)PROPIONIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2471792-A1 | 3-(BIARYLOXY) PROPIONIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245152-A1 | 3-(BIARYOXY)PROPIONIC ACID DERIVATIVE | F11, PF4, F2 | CA1 2137/4885CA9 1288/4885MEN1 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.